{"id":1865,"date":"2019-09-26T13:10:14","date_gmt":"2019-09-26T11:10:14","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=1865"},"modified":"2024-10-03T15:06:27","modified_gmt":"2024-10-03T13:06:27","slug":"metabolism-and-cancer","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/cancer-area\/molecular-mechanisms-and-experimental-therapy-in-oncology-program-oncobell\/metabolism-and-cancer\/","title":{"rendered":"Metabolism and Cancer"},"content":{"rendered":"\n

\n\t\tMetabolism and cancer\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\t

The Metabolism and Cancer group includes Doctors George Thomas, Sara Kozma, Albert Tauler and Antonio Gentilella. The program focuses on the kinase signalling of the mammalian target of rapamycin complex 1 (mTORC1) and its main metabolic cascade responses, including ribosome biogenesis, control of translation, metabolic reprogramming, autophagy, lysosomal transport and cell proliferation. The group’s aim is to unveil metabolic vulnerabilities in cancer to promote new clinical treatments, using colorectal cancer (CRC) and other c-MYC driven tumor models and by interacting with oncologists and pharmaceutical companies.<\/p>\n

415<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"metabolism-and-cancer3\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t